Biotechnology

Applied Therapeutics

Applied Therapeutics Exploring Strategic Options to Maximize Shareholder Value

Applied Therapeutics released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 1 M (forecast USD 250 K), actual EPS USD -0.1304 (forecast USD -0.1566)

Applied Therapeutics released FY2025 9 Months Earnings on November 13 (EST), with actual revenue of USD 1M and EPS of USD -0.4311

Applied Therapeutics released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.2999

Applied Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 312.5K), actual EPS USD -0.1499 (forecast USD -0.1666)

Applied Therapeutics Displays Govorestat CMT-SORD Trial Results

RBC Maintains Applied Therapeutics Rating

Applied Therapeutics released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 10 M), actual EPS USD -0.1507 (forecast USD -0.1774)

Applied Therapeutics Inc. Reports Reduced Net Loss in Q1 2025

Applied Therapeutics AT-007 Data for SORD Deficiency Phase III Trial Accepted

Propel Bio Management Increases Stake in Applied Therapeutics

Applied Therapeutics released FY2024 annual earnings on April 15 (EST), actual revenue USD 455 K (forecast USD 553 K), actual EPS USD -0.76 (forecast USD -1.3263)

Applied Therapeutics released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 100 K), actual EPS USD 0.3017 (forecast USD -0.1737)

Trump's Tariff Policy Leads to Significant Decline in Small-Cap Index

Applied Therapeutics to announce quarterly earnings on March 5, expecting a loss of $0.15 per share

Frank R. Cruz Law Firm Files Class Action Lawsuit Against Applied Therapeutics and Kaspi.kz

Application Therapy Company Receives Notification from Nasdaq Regarding Non-Compliance with Minimum Bid Price

Bleichmar Fonti & Auld LLP Files Lawsuit Against Applied Therapeutics for Alleged Violation of Federal Securities Laws

Faruqi & Faruqi, LLP Investigates Potential Claims Against Applied Therapeutics, Inc.

Faruqi & Faruqi, LLP Investigates Potential Claims Against Applied Therapeutics, Inc. for Violating Securities Laws

Black Titan

Petmed Express

Agape ATP

AXIL Brands

SMX Security Matters

Diamond Hill Investment

Leverage Shares 2X Long GEMI Daily ETF

HeartBeam

Mawson Infrastructure

Planet Labs

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap